rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ROIV
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Roivant at Jefferies Global Healthcare Conference: multiple shots on goal
      Nov 17Investing.comROIVJEF
      How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV)

      Roivant Sciences reported second quarter 2026 revenue of US$35.12 million and a net loss of US$191.62 million, and confirmed completion of a US$393.94 million share repurchase program that retired 13,632,008 shares. The first commercial weeks of LISRIA generated US$31 million in net revenue and were accompanied by encouraging data readouts across IMVT-1402, Mosliciguat and brepocitinib, highlighting how Roivant Sciences is pairing clinical progress with early product uptake. We will now...

      Nov 12Yahoo FinanceROIV
      Don’t Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum (ROIV)
      Nov 11Seeking AlphaROIV
      Roivant Sciences Ltd (ROIV) (Q2 2026) Earnings Call Highlights: LISRIA Launch Delivers $31 ...
      Nov 10Yahoo FinanceROIV
      Roivant Sciences Q2 Earnings Call Highlights
      Nov 9Yahoo FinanceROIV
      What Immunovant (IMVT) Said on Its Q2 Earnings Call
      Nov 9Yahoo FinanceIMVTROIV
      Roivant Q3 2026 slides: LISRAYA launch, pipeline progress drive growth
      Nov 9Investing.comROIV
      Roivant Sciences Q2 2027 Earnings Call Transcript
      Nov 9BenzingaROIV
      Roivant Sciences earnings beat by $0.10, revenue topped estimates
      Nov 9Investing.comROIV
      Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
      Nov 9Yahoo FinanceROIV
      S&P 500 Futures Up in Premarket Trading; Immunovant, Roivant Sciences Lead
      Nov 9Barron'sROIV
      Roivant in the spotlight as earnings loom post-FDA win
      Nov 9Investing.comROIV
      Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
      Nov 6BenzingaROIV
      Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value

      Roivant Sciences has seen its stock deliver significant gains in recent years, which naturally raises the question of whether the current share price still lines up with the value on its balance sheet. With the stock now reflecting years of optimism, investors are asking how that compares with what its book value can support. Over the past 5 years, Roivant Sciences has returned about 383.9%. This puts a lot of weight on whether the underlying net assets justify where the share price has...

      Nov 5Yahoo FinanceROIV
      Ramaswamy Remade Himself In Trump’s Image. Ohio Rejected Him.
      Nov 4ForbesROIV
      Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
      Oct 29Yahoo FinanceROIV
      If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
      Oct 28BenzingaROIV
      Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow
      Oct 24Seeking AlphaROIV
      Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials
      Oct 23Yahoo FinanceROIV
      Roivant reports strong Phase 3 data in uveitis

      Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

      Oct 22The Globe and MailROIV
      Why Is Roivant Sciences Stock Surging Wednesday?
      Oct 21BenzingaROIV
      Stocks making the biggest moves midday: SpaceX, Meta Platforms, Super Micro Computer, Roivant Sciences & more

      Here are some of the companies making headlines in midday trading.

      Oct 21CNBCROIV
      Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results
      Oct 21Yahoo FinanceROIV
      Why is Roivant Sciences stock rallying today?
      Oct 21Investing.comROIV
      Roivant stock gains on late-stage trial win (ROIV:NASDAQ)
      Oct 21Seeking AlphaROIV
      Roivant Sciences stock surges on positive uveitis trial data
      Oct 21Investing.comROIV
      Roivant Sciences' Brepocitinib Achieves Primary Endpoint in Two Phase 3 Trials in Non-Infectious Uveitis
      Oct 21Yahoo FinanceROIV
      Roivant’s brepocitinib meets primary endpoint in uveitis trials
      Oct 21Investing.comROIV
      Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
      Oct 21MorningstarROIV
      Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
      Oct 21Yahoo FinanceROIV
      Roivant Sciences (ROIV) Stock Looks Fully Priced After A 393% Run
      Oct 19Yahoo FinanceROIV
      Roivant Sciences added to Citi's 90-day catalyst watch

      Citi adds Roivant to its 90-day catalyst watch ahead of CLARITY phase 3 brepocitinib data. Read more here.

      Oct 13Seeking AlphaROIV
      Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)

      Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailPVLAROIV
      Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years - Roivant Sciences

      Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 30.08% on an annualized basis producing an average annual return of 41.86%. Currently, Roivant Sciences has a market capitalization of

      Oct 12BenzingaROIV
      Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

      On Thursday, Roivant Sciences (NASDAQ:ROIV) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive

      Oct 5BenzingaROIV
      Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years - Roivant Sciences

      Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization of

      Oct 1BenzingaROIV
      Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months

      Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

      Sep 28Yahoo FinanceIMVTROIV
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

      Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

      Sep 27The Globe and MailROIV
      Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

      Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]

      Sep 24Yahoo FinanceROIV
      Cantor Fitzgerald reiterates Roivant Sciences stock rating
      Sep 24Investing.comROIV
      Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 24The Globe and MailROIVVRTX
      Roivant reports top-line data from IMVT-1402 CLE trial

      This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.

      Sep 24Yahoo FinanceIMVTROIV
      Why Is Immunovant Stock Falling Wednesday? - Roivant Sciences (NASDAQ:ROIV), Immunovant (NASDAQ:IMVT)

      Immunovant halts IMVT-1402 CLE trial after missing primary endpoints, driving IMVT and Roivant shares down in premarket trading.

      Sep 23BenzingaIMVTROIV
      Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss

      Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.

      Sep 23Yahoo FinanceIMVTROIV
      Roivant slips on trial setback for Immunovant (ROIV:NASDAQ)
      Sep 23Seeking AlphaIMVTROIV
      Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

      Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant’s internal bar to continue development of IMVT-140

      Sep 23Yahoo FinanceIMVTROIV
      Roivant at Bank of America Global Healthcare Conference: pipeline momentum builds
      Sep 22Investing.comROIVBAC
      Roivant (ROIV): $9 Billion Sales Potential Faces a Commercialization Test

      Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]

      Sep 22Yahoo FinanceROIV
      Ohio Governor Ramaswamy Would Be America’s Third-Richest Elected Official
      Sep 20ForbesROIVH
      Roivant Shareholders Approve Directors and Governance Matters

      Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailROIV

      This is the newest page. Registered accounts read further back.